Creative Medical Technology Holdings (CELZ) Free Cash Flow (2011 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Free Cash Flow of -$1.3 million for Q1 2026, up 16.85% year-over-year from -$1.1 million in Q1 2025, and up 31.7% quarter-over-quarter from -$1.9 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Free Cash Flow (2011 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Free Cash Flow for 16 consecutive years, with -$1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 16.85% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at -$5.6 million (up 6.8% YoY), while the FY2025 annual figure was -$5.9 million, down 10.47% from the prior year.
- Free Cash Flow advanced to -$1.3 million in Q1 2026 per CELZ's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$873303.0 in Q3 2022 and bottomed at -$3.8 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$1.7 million across 5 years, with a median of -$1.5 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 690.29% — and 2024, when it soared 76.65%.
- Creative Medical Technology Holdings' Free Cash Flow stood at -$3.6 million in 2022, then surged by 47.23% to -$1.9 million in 2023, then slipped by 2.88% to -$1.9 million in 2024, then rose by 0.61% to -$1.9 million in 2025, then soared by 31.7% to -$1.3 million in 2026.
- Business Quant data shows CELZ's Free Cash Flow at -$1.3 million in Q1 2026, -$1.9 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | -1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.47 Mn |
| Jun 30, 2026 | -1.47 Mn |
| Mar 31, 2026 | -1.32 Mn |
| Mar 31, 2026 | -1.32 Mn |
| Dec 31, 2025 | -1.94 Mn |
| Dec 31, 2025 | -1.94 Mn |
| Sep 30, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.17 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | -985,588.00 |
| Sep 30, 2024 | -985,588.00 |
| Jun 30, 2024 | -1.47 Mn |
| Jun 30, 2024 | -1.47 Mn |
| Mar 31, 2024 | -896,864.00 |
| Mar 31, 2024 | -896,864.00 |